industry and will bring value to all practices, both |
Philips ' AlluraClarity was commercially |
international pharmaceutical company, SK |
large and small. The addition of Mentor ' s breast |
introduced outside the US in mid-2012, and since |
Biopharmaceuticals, and the Korea-based |
aesthetic portfolio is truly exciting news for our |
then more than 200 systems have been ordered. |
emerging biotech, AriBio, have entered into a |
customers and we are excited about future |
With this important milestone of FDA clearance, |
collaboration agreement for SK |
iterations of the programme to come." |
the system can now be marketed in the world ' s |
Biopharmaceuticals ' novel new small molecule |
Valeant Pharmaceuticals International, |
largest healthcare market. |
SKL-G that is being developed for the treatment of |
Inc. is a multinational specialty pharmaceutical |
PHARMACEUTICAL PACKAGING |
glaucoma. |
company that develops, manufactures and markets |
PRODUCTS SUPPLIER, CHESAPEAKE:
The
|
Dr. Christopher Gallen, CEO and |
a broad range of pharmaceutical products primarily |
Carlyle Group, a global alternative asset manager, |
president of SK Biopharmaceuticals, said,“ While |
in the areas of dermatology, neurology and |
has acquired Chesapeake, one of the largest global |
focused on the disorders and mechanisms of the |
branded generics. |
suppliers of value-added paper-based packaging |
nervous system, the powerful SK |
ROYAL PHILIPS ' ALLURACLARITY LIVE |
products and services from Irving Place Capital |
Biopharmaceuticals Third Wave discovery |
|
IMAGE GUIDANCE SYSTEM:
Royal Philips
|
and funds managed by Oaktree Capital |
platform creates compounds that are also relevant |
has received 510( k) clearance from the US Food |
Management. |
to diseases in other body systems, in this case, the |
and Drug Administration( FDA) to market its |
Capital for this investment will come |
eye. Through this agreement, both companies can |
innovative AlluraClarity live image guidance |
from Carlyle Europe Partners III L. P., a € 5.3 |
realize a creative drug development process by |
system in the US. |
billion fund that makes mid- and large-cap |
sharing R & D capabilities, know-how, and |
In close collaboration with leading clinicians in the |
investments. Further terms of the investment were |
experiences.” |
field of minimally-invasive medicine, Philips has |
not disclosed. |
Dr. Soo-Hyun Sung, CEO and president |
been driving innovation in interventional imaging |
Headquartered in Nottingham, UK, and |
of AriBio, said,“ This agreement recognizes |
for more than 50 years, helping to guide |
with nearly 5,000 employees across 38 sites in 9 |
AriBio ' s capabilities in drug discovery and |
procedures such as the catheter-based treatment of |
countries, Chesapeake is a high quality and |
development for ophthalmologic disorders. Also, it |
obstructed coronary arteries, brain aneurysms, |
premium producer of paper-based leaflets, labels |
is an excellent example of collaboration between a |
heart rhythm disorders and defective heart valves |
and cartons, primarily for the pharmaceutical, |
medium-sized venture company and a major |
( heart valve replacement). |
confectionery and premium drinks markets for a |
conglomerate.” |
Philips ' AlluraClarity system with its |
blue-chip client base. Chesapeake has grown |
SK Biopharmaceuticals has discovered |
powerful ClarityIQ technology provides high |
significantly in recent years to produce revenues of |
this innovative drug candidate and has evaluated |
quality imaging for a comprehensive range of |
€ 580 million in 2012. |
its potential in animal models with AriBio since |
clinical procedures, achieving excellent visibility |
Eric Kump, managing director Carlyle |
2012. The animal experiments showed that SKL-G |
at low X-ray dose levels for patients of all sizes. To |
Europe Partners, said:“ Chesapeake is a strong |
successfully prevented optic nerve cell death and, |
reflect the cost pressures that modern hospitals and |
business focused on attractive growth markets. |
in addition, lowered intraocular pressure that is one |
health systems face, ClarityIQ technology will also |
The management team has delivered sustained |
of the major causes of glaucoma. |
be available as an upgrade for the majority of |
growth and significantly strengthened the company |
Most currently-marketed glaucoma drugs have |
Philips ' installed base of monoplane and biplane |
in recent years. We look forward to partnering |
only symptomatic treatment effects, lowering |
interventional X-ray systems. |
with them to further develop the company ' s |
intraocular pressure, but they fail to address the |
“ All patients treated via X-ray guided |
international footprint and to invest in delivering |
disease process itself, eventually resulting in |
interventions benefit from the advantage of low |
industry leading products and services. We believe |
blindness. Thus fundamental therapies that can |
radiation exposure, but it is especially important |
the combination of Carlyle ' s global presence and |
prevent optic nerve cell death represent an |
when you are treating patients who have to |
network and the strength of the company ' s existing |
enormous unmet medical need. |
undergo lengthy and complex procedures,” said |
footprint and customer relationships will help drive |
Because the evaluation results fully |
Dr. Marco van Strijen, interventional radiologist at |
significant growth and new market opportunities in |
supported the competitive advantage of SKL-G |
the St. Antonius Hospital Utrecht / Nieuwegein, the |
the coming years.” |
over existing therapies, the decision was made to |
Netherlands.“ We have been using Philips ' |
Mike Cheetham, chief executive officer of |
form a strategic alliance for preclinical and clinical |
AlluraClarity system for more than a year now and |
Chesapeake commented:“ We are delighted to have |
development. |
have really grown to appreciate the low dose |
Carlyle working with us as we continue building |
SK biopharmaceuticals and AriBio have |
settings. This technology is making a difference |
on the strong reputation we have earned for our |
agreed to complete preclinical development shortly |
where it really matters." |
high quality products and services. Carlyle ' s |
and then start clinical trials following an |
“ The transition from highly invasive |
backing will support our aspirations to build upon |
Investigational New Drug( IND) application to US |
surgical procedures to minimally-invasive image- |
our strong investments over the past three years as |
FDA. They are also considering various strategic |
guided therapies, with all their intrinsic patient |
we further grow and develop our business. This |
options for partnering and commercialization. |
benefits, is a transformation in the delivery of |
collaboration will allow us to respond effectively |
The market size for glaucoma treatments is |
healthcare that is rapidly accelerating around the |
to new business opportunities as we look to further |
estimated to be over $ 3 billion in 2010, and the |
globe,” said Gene Saragnese, CEO Imaging |
align our business with our customers ' global |
market might be quite larger if other |
Systems at Philips Healthcare.“ It is an area where |
requirements.” |
ophthalmology disorders such as age-related |
technology innovation and procedure innovation |
The Carlyle Group is a global alternative |
macular degeneration are considered. SK |
go hand in hand. AlluraClarity is a perfect example |
asset manager with $ 176 billion of assets under |
Biopharmaceuticals is a global pharmaceutical |
of how Philips ' close collaboration with clinical |
management across 114 funds and 76 fund of |
company that was spun out in April 2011 from SK |
partners has combined these two areas of |
funds vehicles as of March 31, 2013. |
Holdings, the third-largest conglomerate in South |
innovation to facilitate more advanced treatment |
Chesapeake is a leading international |
Korea. SK Biopharmaceuticals focuses on the |
while at the same time managing radiation dose.” |
supplier of consumer packaging. The business, |
discovery and development of new drugs for the |
AlluraClarity ' s low X-ray dose settings |
focused on quality and innovation, supplies |
treatment of central nervous system disorders. |
are a radical new development in the healthcare |
paperboard products to the pharmaceutical and |
AriBio is one of the emerging biotech |
industry that will help clinicians to better manage |
premium consumer goods markets. The company |
companies in Korea specializing in new drug |
their patients ' and their own exposure to X-ray |
produces a full range of folding cartons, leaflets |
development in various areas with high unmet |
radiation. This achievement is the result of a multi- |
and labels at 37 locations in Asia, Europe and the |
medical needs such as ophthalmology. |
year development program that formed part of |
United States. |
|
Philips ' continuous investment in healthcare R & D, |
NEW SMALL MOLECULE FOR |
|
totaling EUR 803 million in 2012. |
GLAUCOMA TREATMENT: The Korea-based |